Bay Street News, 2024

All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization […]

All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) […]

– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off […]

WISeKey Announces Retirement of Peter Ward as Chief Financial Officer; Appoints John O’Hara as its New Chief Financial Officer Geneva, […]

Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy, and […]

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed […]

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing […]

NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development […]

KIRKLAND, Wash., June 13, 2024 (GLOBE NEWSWIRE) — Monolithic Power Systems, Inc. (Nasdaq: MPWR), a global company that provides high-performance, […]

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that Arm Holdings plc (Nasdaq: ARM), will […]